|drug1780||Ketamine Hydrochloride Wiki||1.00|
|drug2149||Naltrexone 380 MG Wiki||1.00|
|D000428||Alcohol Drinking NIH||0.45|
There is one clinical trial.
Every year, alcohol use disorder (AUD) generates millions of emergency department (ED) visits and hospital admissions, costing the U.S. health sector over $90 billion. These hospital admissions are critical opportunities to start patients on addiction pharmacotherapy, but factors like medication non-adherence and post-discharge relapse contribute to frequent re-admissions. Two single-dose interventions are well suited to facilitate treatment retention and prevent re-admissions due to their prolonged, adherence-independent effects: extended-release (XR) naltrexone injection and intravenous (IV) ketamine infusion. These have not been thoroughly investigated in the hospital setting among high-utilizer, safety-net populations. Therefore, the investigators aim to: 1. Test the feasibility of randomizing hospitalized patients (n=45-60, age 18-65) with multiple AUD-related admissions to treatment with either extended-release (XR) naltrexone, intravenous (IV) ketamine, or no single-dose medication, all with enhanced linkage to care. Feasibility outcomes such as recruitment rate, patient acceptability, post-discharge follow-up rate, and adverse events will help to identify key lessons for a future comparative effectiveness study. 2. Estimate the 30-day re-admission rate for patients randomized to treatment with XR naltrexone, with IV ketamine, or no single-dose medication, all with enhanced linkage to care. The investigators hypothesize that the re-admission rate will be lower for each of the two single-dose medication groups than for the "linkage-alone" group.
Description: Binary outcome: any all-cause hospitalization ascertained by chart review (our EHR includes records from several local hospitals)Measure: Rate (%) of 30-day hospital re-admission Time: Within 30 days of index hospital discharge. The enrollment period is 5 months.
Description: Number of participants recruited per month during the enrollment periodMeasure: Feasibility - recruitment rate (# per month) Time: The enrollment period is 5 months
Description: Percentage of patients who presented to 1 week follow-up appointmentMeasure: Feasibility - follow-up rate (%) Time: The enrollment period is 5 months
Description: Within-subject differences in readiness to change between inpatient enrollment and outpatient follow-up.Measure: Average within-subject difference in readiness-to-change (SOCRATES-8A score) Time: Follow-up planned to be within one week of discharge
Description: Binary outcome: any all-cause ED visit ascertained by chart reviewMeasure: Rate (%) of 30-day emergency department visit Time: Within 30 days of index hospital discharge. The enrollment period is 5 months.
Description: Obtained by urine EtG at outpatient follow-upMeasure: Rate (%) of urine Ethyl Glucuronide (EtG) at follow-up Time: Follow-up planned to be within one week of discharge. The enrollment period is 5 months.
Description: Self reported at outpatient follow-up, ascertained by Timeline Follow-Back Method.Measure: Rate (%) of self-reported binge drinking since discharge Time: Follow-up planned to be within one week of discharge. The enrollment period is 5 months.
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports